118 related articles for article (PubMed ID: 38695144)
61. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
62. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
Yao H; Zhang C; Tan X; Li J; Yin X; Deng X; Chen T; Rao J; Gao L; Kong P; Zhang X
Cancer Med; 2023 Jun; 12(11):12377-12387. PubMed ID: 37161845
[TBL] [Abstract][Full Text] [Related]
63. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Sakura T; Kanamori H; Usuki K; Yamashita T; Okoshi Y; Shibayama H; Nakamae H; Mawatari M; Hatanaka K; Sunami K; Shimoyama M; Fujishima N; Maeda Y; Miura I; Takaue Y; Fukuda T
Haematologica; 2010 Nov; 95(11):1857-64. PubMed ID: 20634493
[TBL] [Abstract][Full Text] [Related]
64. Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.
Im A; Amjad A; Agha M; Raptis A; Hou JZ; Farah R; Lim S; Sehgal A; Dorritie KA; Redner RL; McLaughlin B; Shuai Y; Duggal S; Boyiadzis M
Oncol Res; 2016; 24(2):73-80. PubMed ID: 27296947
[TBL] [Abstract][Full Text] [Related]
65. Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
Yuasa M; Yamamoto H; Mitsuki T; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Wake A; Koike Y; Makino S; Uchida N; Taniguchi S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2262-2270. PubMed ID: 32871257
[TBL] [Abstract][Full Text] [Related]
66. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
Short NJ; Ong F; Ravandi F; Nogueras-Gonzalez G; Kadia TM; Daver N; DiNardo CD; Konopleva M; Borthakur G; Oran B; Al-Atrash G; Mehta R; Jabbour EJ; Yilmaz M; Issa GC; Maiti A; Champlin RE; Kantarjian H; Shpall EJ; Popat U
Blood Adv; 2023 Jul; 7(14):3573-3581. PubMed ID: 37104058
[TBL] [Abstract][Full Text] [Related]
67. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.
Wagner K; Damm F; Thol F; Göhring G; Görlich K; Heuser M; Schäfer I; Schlegelberger B; Heil G; Ganser A; Krauter J
Haematologica; 2011 May; 96(5):681-6. PubMed ID: 21242187
[TBL] [Abstract][Full Text] [Related]
68. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse.
Lim ABM; Curley C; Fong CY; Bilmon I; Beligaswatte A; Purtill D; Getta B; Johnston AM; Armytage T; Collins M; Mason K; Fielding K; Greenwood M; Gibson J; Hertzberg M; Wright M; Lewis I; Moore J; Curtis D; Szer J; Kennedy G; Ritchie D
Intern Med J; 2018 Mar; 48(3):276-285. PubMed ID: 28628276
[TBL] [Abstract][Full Text] [Related]
69. Acute Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The Good, the Bad, and the Ugly of Isolated Extramedullary Relapse in a Latin American Population.
Arias-Espinosa L; Acosta-Medina AA; Vargas-España A; Fuentes-Martin V; Colunga-Pedraza PR; Hawing-Zarate JA; Leon AG; Soto-Mota A; Pacheco-Gutierrez G; Vargas-Serafín C; Barrera-Lumbreras G; Bourlon C
Transplant Cell Ther; 2023 Aug; 29(8):510.e1-510.e9. PubMed ID: 37169289
[TBL] [Abstract][Full Text] [Related]
70. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
[TBL] [Abstract][Full Text] [Related]
71. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
[No Abstract] [Full Text] [Related]
72. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
[No Abstract] [Full Text] [Related]
73. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.
Leung AY; Tse E; Hwang YY; Chan TS; Gill H; Chim CS; Lie AK; Kwong YL
Am J Hematol; 2013 Jun; 88(6):485-91. PubMed ID: 23512868
[TBL] [Abstract][Full Text] [Related]
74. A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.
Rashidi A; Cashen AF
Leuk Res; 2015 Jan; 39(1):77-81. PubMed ID: 25481050
[TBL] [Abstract][Full Text] [Related]
75. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
76. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
77. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.
Begna KH; Kittur J; Gangat N; Alkhateeb H; Patnaik MS; Al-Kali A; Elliott MA; Hogan WJ; Litzow MR; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2022 Jan; 12(1):7. PubMed ID: 35039473
[TBL] [Abstract][Full Text] [Related]
78. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
79. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
80. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience.
Yu Z; Yao Y; Zhang Y; Chen J; Xu Y; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Wu D; Wang Y
Hematology; 2023 Dec; 28(1):2212534. PubMed ID: 37191301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]